Sunday, 04 December 2022

Siemens Healthineers obtains first FDA EUA authorization for COV2G Ab test

05 August 2020 | News

The SARS-CoV-2 IgG Antibody Test offers the first EUA-authorized semi-quantitative assay to help clinicians assess the level of an individual’s immune response.

image credit-

image credit-

German fim Siemens Healthineers has announced that it has received FDA Emergency Use Authorization (EUA) for the SARS-CoV-2 IgG (COV2G) antibody (Ab) test. This is the first antibody test authorized with a semi-quantitative detection claim and the fifth antibody test from the company to receive EUA that offers sensitivity and specificity of greater than 99 %. The COV2G antibody test offers both a positive or negative result for IgG antibodies and reports a numerical result expressed as index value.

The COV2G antibody test, and all SARS-CoV-2 antibody tests from Siemens Healthineers, detect antibodies to S1RBD. Multiple potential vaccines in development for SARS-CoV-2 include the spike protein, specifically S1RBD—a key protein on the surface of the SARS-CoV-2 virus—within their focus.

The COV2G antibody test is available on an expansive installed base of analyzers installed in the U.S. and in countries that accept the CE mark worldwide. SARS-CoV-2 Total antibody assay [COV2T] is currently being used by several reputed clinical laboratories and institutions on the company's reliable high throughput automated chemiluminescence analyzers including Atellica Solution, ADVIA Centaur and Dimension EXL series for sero-surveillance.

SARS-CoV-2 Total antibody assay [COV2T] that detects both IgM and longer-lasting IgG antibodies is available in India since June 2020.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account